Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

LatviaBack to Latvia

Clinical trials in Riga – page 5

203 clinical trials in Riga, Latvia across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

LatviaOur site in LatviaKliniskiePetijumi.lv(opens in a new tab)
Riga at a glance
203
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

203 trials in Riga

Open in trial search

Acute myeloid leukaemia

Recruiting

Study on the Safety and Effectiveness of Quizartinib for Children with Newly Diagnosed FLT3-ITD Positive AML and Normal NPM1

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:0–17 years · 18–64 years
  • Substances:Quizartinib Dihydrochloride
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Ectopic pregnancy

Recruiting

Study on Mifepristone and Letrozole for Treating Ectopic Pregnancy in Comparison to Methotrexate

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years
  • Substances:Letrozole
  • Sponsor:Karolinska Institutet

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Peripheral arterial occlusive disease

Not yet recruiting

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:REGN7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Osteoporosis postmenopausal

Not yet recruiting

Study on the Effects of BP16 and Denosumab in Women with Post-Menopausal Osteoporosis

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Curateq Biologics Private Limited

Pulmonary arterial hypertension+1

Not yet recruiting

Safety and Efficacy of Extended‑Release Tacrolimus (VI‑0106) in Adults with Pulmonary Arterial Hypertension and Functional Limitations

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus

Primary biliary cholangitis

Not yet recruiting

Safety and Efficacy of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis: A Long‑Term Randomized Placebo‑Controlled Study

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years
  • Substances:Saroglitazar hemimagnesium
  • Sponsor:Zydus Therapeutics Inc.

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:REGN7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

Myasthenia gravis

Not yet recruiting

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Neovascular age-related macular degeneration

Not yet recruiting

Safety and Efficacy of Two Doses of OCUL101 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:65+ years
  • Substances:Aflibercept

Other cities in Latvia

The busiest research cities in the country

All 19 cities in Latvia

Clinical research in Riga

What the registry says about research in the country

01 Immunology & Vaccines

Research focusing on vaccine development and immune responses, including studies of combined vaccines for childhood diseases and immune system modulation in various conditions.

  • Measles-Mumps-Rubella-Varicella vaccine studies
  • Primary Immune Thrombocytopenia treatments
  • Novel immunotherapy approaches
02 Metabolic & Endocrine Disorders

Investigations into metabolic conditions and hormone-related disorders, with emphasis on treatment innovations and management strategies.

  • Glucagon response studies
  • Hypertriglyceridemia management
  • Post-menopausal osteoporosis treatment
03 Inflammatory Conditions

Clinical research targeting various inflammatory diseases, including dermatological and rheumatological conditions.

  • Psoriatic arthritis treatments
  • Plaque psoriasis therapies
  • Ulcerative colitis interventions
04 Oncology & Neurology

Studies focusing on innovative treatments for cancer and neurological disorders, including targeted therapies and combination approaches.

  • Non-small cell lung cancer treatments
  • Glioblastoma therapy
  • Dravet Syndrome management
05 Respiratory & Cardiovascular

Research into pulmonary conditions and heart-related disorders, exploring new therapeutic approaches.

  • Pulmonary arterial hypertension
  • Asthma treatment innovations
  • Heart failure interventions
Back to LatviaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.